Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04925856 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunomonitoring of Breast Cancer Patients During Systemic Treatment

Study acronym: IMMUNE CAPTURE
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: May 26, 2023 to May 26, 2030 Completion date: May 26, 2024 to May 26, 2030v3 Show 1 more changeShow less
    • Completion date: May 26, 2024 to May 26, 2030
  2. Primary completion date: May 26, 2022 to May 26, 2023 Completion date: May 26, 2028 to May 26, 2024v2 Show 1 more changeShow less
    • Completion date: May 26, 2028 to May 26, 2024
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe the basal immune response of patients treated for a breast cancer according to the stage of the disease, but above all to study how the different systemic treatments used in the management of breast cancer modulate this immune response.
Trial Details
NCT Number NCT04925856
Lead Sponsor Centre Georges Francois Leclerc
Conditions Breast Cancer
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov